Cargando…

Characteristics of HBV Novel Serum Markers across Distinct Phases in Treatment-Naïve Chronic HBV-Infected Patients

METHODS: A total of 111 patients in total from different disease phases were recruited, including 21 in immune-tolerant (IT) phase, 49 in immune-clearance (IC) phases, 29 in immune-control or low replicative (LR) phase, and 12 in reactivation phases. Serum HBV RNA, anti-HBc, HBcrAg, and intrahepatic...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Hao, Li, Le, Zheng, Wei V., Zou, Jun, Yu, Guangxin, Si, Lanlan, Ge, Feilin, Zhou, Tao, Ji, Dong, Chen, Xiangmei, Xu, Dongping, Cheng, Guanxun, Liu, Yan, Chen, Junhui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303147/
https://www.ncbi.nlm.nih.gov/pubmed/35872701
http://dx.doi.org/10.1155/2022/4133283
_version_ 1784751790956216320
author Liao, Hao
Li, Le
Zheng, Wei V.
Zou, Jun
Yu, Guangxin
Si, Lanlan
Ge, Feilin
Zhou, Tao
Ji, Dong
Chen, Xiangmei
Xu, Dongping
Cheng, Guanxun
Liu, Yan
Chen, Junhui
author_facet Liao, Hao
Li, Le
Zheng, Wei V.
Zou, Jun
Yu, Guangxin
Si, Lanlan
Ge, Feilin
Zhou, Tao
Ji, Dong
Chen, Xiangmei
Xu, Dongping
Cheng, Guanxun
Liu, Yan
Chen, Junhui
author_sort Liao, Hao
collection PubMed
description METHODS: A total of 111 patients in total from different disease phases were recruited, including 21 in immune-tolerant (IT) phase, 49 in immune-clearance (IC) phases, 29 in immune-control or low replicative (LR) phase, and 12 in reactivation phases. Serum HBV RNA, anti-HBc, HBcrAg, and intrahepatic covalently closed circular DNA (cccDNA) were quantified and each of these indicator's correlation with liver inflammation was analyzed. RESULTS: HBeAg-positive individuals had significant higher serum levels of HBV RNA and HBcrAg than those who were HBeAg negative, similar to that of serum HBV DNA. Comparatively, HBV RNA (r =0.79, P < 0.01) and HBcrAg (r =0.78, P < 0.01) had almost same higher overall correlation with the cccDNA, as that of HBV DNA (r =0.81, P < 0.01). Serum anti-HBc level (r = -0.52, P < 0.05) is negatively correlated with cccDNA level at IT phase rather than the other three phases. When set the cutoff value at 4.00 log(10) IU/mL, serum anti-HBc showed potential to indicate liver inflammation, with AUC as 0.79 and the specificities as 78.85% for HBeAg positive, and with AUC as 0.72 and the specificities as 62.16% for HBeAg-negative patients, respectively. CONCLUSIONS: In treatment-naïve patients, levels of serological markers HBV RNA and HBcrAg could mirror intrahepatic cccDNA level, but were not superior to HBV DNA level. Serum anti-HBc level had certain potential to be used as a predicting marker for liver inflammation.
format Online
Article
Text
id pubmed-9303147
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-93031472022-07-22 Characteristics of HBV Novel Serum Markers across Distinct Phases in Treatment-Naïve Chronic HBV-Infected Patients Liao, Hao Li, Le Zheng, Wei V. Zou, Jun Yu, Guangxin Si, Lanlan Ge, Feilin Zhou, Tao Ji, Dong Chen, Xiangmei Xu, Dongping Cheng, Guanxun Liu, Yan Chen, Junhui Dis Markers Research Article METHODS: A total of 111 patients in total from different disease phases were recruited, including 21 in immune-tolerant (IT) phase, 49 in immune-clearance (IC) phases, 29 in immune-control or low replicative (LR) phase, and 12 in reactivation phases. Serum HBV RNA, anti-HBc, HBcrAg, and intrahepatic covalently closed circular DNA (cccDNA) were quantified and each of these indicator's correlation with liver inflammation was analyzed. RESULTS: HBeAg-positive individuals had significant higher serum levels of HBV RNA and HBcrAg than those who were HBeAg negative, similar to that of serum HBV DNA. Comparatively, HBV RNA (r =0.79, P < 0.01) and HBcrAg (r =0.78, P < 0.01) had almost same higher overall correlation with the cccDNA, as that of HBV DNA (r =0.81, P < 0.01). Serum anti-HBc level (r = -0.52, P < 0.05) is negatively correlated with cccDNA level at IT phase rather than the other three phases. When set the cutoff value at 4.00 log(10) IU/mL, serum anti-HBc showed potential to indicate liver inflammation, with AUC as 0.79 and the specificities as 78.85% for HBeAg positive, and with AUC as 0.72 and the specificities as 62.16% for HBeAg-negative patients, respectively. CONCLUSIONS: In treatment-naïve patients, levels of serological markers HBV RNA and HBcrAg could mirror intrahepatic cccDNA level, but were not superior to HBV DNA level. Serum anti-HBc level had certain potential to be used as a predicting marker for liver inflammation. Hindawi 2022-07-14 /pmc/articles/PMC9303147/ /pubmed/35872701 http://dx.doi.org/10.1155/2022/4133283 Text en Copyright © 2022 Hao Liao et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Liao, Hao
Li, Le
Zheng, Wei V.
Zou, Jun
Yu, Guangxin
Si, Lanlan
Ge, Feilin
Zhou, Tao
Ji, Dong
Chen, Xiangmei
Xu, Dongping
Cheng, Guanxun
Liu, Yan
Chen, Junhui
Characteristics of HBV Novel Serum Markers across Distinct Phases in Treatment-Naïve Chronic HBV-Infected Patients
title Characteristics of HBV Novel Serum Markers across Distinct Phases in Treatment-Naïve Chronic HBV-Infected Patients
title_full Characteristics of HBV Novel Serum Markers across Distinct Phases in Treatment-Naïve Chronic HBV-Infected Patients
title_fullStr Characteristics of HBV Novel Serum Markers across Distinct Phases in Treatment-Naïve Chronic HBV-Infected Patients
title_full_unstemmed Characteristics of HBV Novel Serum Markers across Distinct Phases in Treatment-Naïve Chronic HBV-Infected Patients
title_short Characteristics of HBV Novel Serum Markers across Distinct Phases in Treatment-Naïve Chronic HBV-Infected Patients
title_sort characteristics of hbv novel serum markers across distinct phases in treatment-naïve chronic hbv-infected patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303147/
https://www.ncbi.nlm.nih.gov/pubmed/35872701
http://dx.doi.org/10.1155/2022/4133283
work_keys_str_mv AT liaohao characteristicsofhbvnovelserummarkersacrossdistinctphasesintreatmentnaivechronichbvinfectedpatients
AT lile characteristicsofhbvnovelserummarkersacrossdistinctphasesintreatmentnaivechronichbvinfectedpatients
AT zhengweiv characteristicsofhbvnovelserummarkersacrossdistinctphasesintreatmentnaivechronichbvinfectedpatients
AT zoujun characteristicsofhbvnovelserummarkersacrossdistinctphasesintreatmentnaivechronichbvinfectedpatients
AT yuguangxin characteristicsofhbvnovelserummarkersacrossdistinctphasesintreatmentnaivechronichbvinfectedpatients
AT silanlan characteristicsofhbvnovelserummarkersacrossdistinctphasesintreatmentnaivechronichbvinfectedpatients
AT gefeilin characteristicsofhbvnovelserummarkersacrossdistinctphasesintreatmentnaivechronichbvinfectedpatients
AT zhoutao characteristicsofhbvnovelserummarkersacrossdistinctphasesintreatmentnaivechronichbvinfectedpatients
AT jidong characteristicsofhbvnovelserummarkersacrossdistinctphasesintreatmentnaivechronichbvinfectedpatients
AT chenxiangmei characteristicsofhbvnovelserummarkersacrossdistinctphasesintreatmentnaivechronichbvinfectedpatients
AT xudongping characteristicsofhbvnovelserummarkersacrossdistinctphasesintreatmentnaivechronichbvinfectedpatients
AT chengguanxun characteristicsofhbvnovelserummarkersacrossdistinctphasesintreatmentnaivechronichbvinfectedpatients
AT liuyan characteristicsofhbvnovelserummarkersacrossdistinctphasesintreatmentnaivechronichbvinfectedpatients
AT chenjunhui characteristicsofhbvnovelserummarkersacrossdistinctphasesintreatmentnaivechronichbvinfectedpatients